Value of the in vitro or in vivo monoethylglycinexylidide test for predicting liver graft function

Transplantation

Volumn 64, Issue 1, 1997, Pages 60-65

  Olinga, Peter ^a,b   Maring, John K ^c   Groothuis, Geny M M ^a   Kranenburg, Koos ^c   Merema, Marjolijn ^a   Hof, Ingrid H ^a   Meijer, Dirk K F ^a   Slooff, Maarten J H ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEETHYLLIDOCAINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DIAGNOSTIC ACCURACY; GRAFT SURVIVAL; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; NEEDLE BIOPSY; PREDICTION; PRIORITY JOURNAL;

ADENOSINE; ALLOPURINOL; GLUTATHIONE; HUMANS; INSULIN; LIDOCAINE; LIVER TRANSPLANTATION; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; RAFFINOSE; TISSUE DONORS;

EID: 0030749457     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00012     Document Type: Article

References (23)

1. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation: a multivariate analysis. Transplantation 1993; 55: 807.
2. Pruim J, Klompmaker IJ, Haagsma EB, Bijleveld CMA, Slooff MJH. Selection criteria for liver donation: a review. Transpl Int 1993; 6: 226.
3. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829.
4. Bargetzi MJ, Aoyama T, Gonzalez PJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46: 521.
5. Oellerich M, Burdelski M, Ringe B, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; 1: 640.
6. Tesi RJ, Elkhammas EA, Davies EA, et al. Safe use of liver donors with MEGX values less than 90 ng/ml. Transplant Proc 1993; 25: 1655.
7. Michell ID, Abdulnour I, Pzybylowski G, et al. Donor hyaluronic acid and MEGX levels do not accurately predict posttransplant liver function. Transplant Proc 1993; 25: 2888.
8. Reding R, Wallemacq P, de Ville de Goyet J, et al. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors. Transplantation 1993; 56: 323.
9. Adam R, Azoulay D, Astarcioglu I, et al. Limits of the MEGX test in the selection of liver grafts for transplantation. Transplant Proc 1993; 25: 1653.
10. Bennett PN, Aarons LJ, Bending MR, Steiner JA, Rowland M. Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. J Pharmacokinet Biopharm 1982; 10: 265.
11. Takata T. Effect of dopamine on lidocaine metabolism in patients after partial liver resection: a pharmacokinetic analysis. Masui 1989; 38: 357.
12. Starzl TE, Hakala TR, Shaw B Jr, et al. A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet 1984; 158: 223.
13. Zoppi F, Fumagalli C. Improved measurement of MEGX in serum with the Abbott TDx. Clin Chem 1992; 38: 441.
14. Sandker GW, Slooff MJH, Groothuis GMM. Drug transport, viability and morphology of isolated rat hepatocytes preserved for 24 hours in University of Wisconsin solution. Biochem Pharmacol 1992; 43: 1479.
15. Olinga P, Merema MT, Meijer DKF, Slooff MJH, Groothuis GMM. Human liver slices express the same lidocaine biotransformation rate as isolated human hepatocytes. Alternatives to Laboratory Animals 1993; 21: 466.
16. Gonzalez FX, Rimola A, Grande L, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994; 20: 565.
17. Meyer B, Luo HS, Bargetzi M, Renner EL, Stalder GA. Quantitation of intrinsic drug-metabolizing capacity in human liver biopsy specimens: support for the intact-hepatocyte theory. Hepatology 1991; 13: 475.
18. Sallie RW, Tredger JM, Williams R. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX). Biopharm Drug Dispos 1992; 13: 555.
19. Steininger R, Roth E, Fugger R, et al. Transhepatic metabolism of TNF-alpha, IL-6, and endotoxin in the early hepatic reperfusion period after human liver transplantation. Transplantation 1994; 58: 179.
20. Chen YL, Florentin I, Batt AM, Ferrari L, Giroud JP, Chauvelot-Moachon L. Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat. Biochem Pharmacol 1992; 44: 137.
21. Monshouwer M, Witkamp RF, Nijmeijer SM, Van Amsterdam JG, Van Miert ASJPAM. Suppression of cytochrome P450- and UDP glucuronosyl transferase dependent enzyme activities by pro-inflammatory citokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 1996; 137: 237.
22. Drayer DE, Lorenzo B, Werns S, Reidenberg MM. Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages. Clin Pharmacol Ther 1983; 34: 14.
23. Venkataramanan R, Habucky K, Burckart GJ, Ptachcinski RJ. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989; 16: 134.